Economic Evaluation of Percutaneous Left Atrial Appendage Occlusion, Dabigatran, and Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation | Zendy

Sheldon M. Singh | Zendy; Andrew Micieli | Zendy; Harindra C. Wijeysundera | Zendy

Open Access

Economic Evaluation of Percutaneous Left Atrial Appendage Occlusion, Dabigatran, and Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation

Author(s) -

Sheldon M. Singh,

Andrew Micieli,

Harindra C. Wijeysundera

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.000920

Subject(s) - medicine , atrial fibrillation , warfarin , left atrial appendage occlusion , dabigatran , stroke (engine) , occlusion , percutaneous , cardiology , cost effectiveness , anesthesia , mechanical engineering , risk analysis (engineering) , engineering

Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effectiveness of LAA occlusion compared with dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research